Safety and efficacy of cilostazol in the management of intermittent claudication

Vasc Health Risk Manag. 2008;4(6):1197-203. doi: 10.2147/vhrm.s3160.


Peripheral arterial disease (PAD) is a major health problem affecting millions of patients worldwide. Many will suffer from intermittent claudication (IC), which leads to marked impairment of quality of life (QoL). Besides surgical and endovascular interventions to improve limb-specific outcomes, pharmacotherapy is an effective tool in the treatment of IC. Cilostazol, a Federal Drug Administration-approved medication for the treatment of IC, has demonstrated consistent efficacy in improving exercise capacity and overall health-related QoL. This manuscript will review the pharmacokinetics, safety, and efficacy of cilostazol in the treatment of patients with IC as well as compare this agent with other proven non-invasive therapies for PAD.

Keywords: cilostazol; intermittent claudication; peripheral arterial disease; supervised exercise therapy.

Publication types

  • Review

MeSH terms

  • Cardiovascular Agents / adverse effects
  • Cardiovascular Agents / pharmacokinetics
  • Cardiovascular Agents / therapeutic use*
  • Cilostazol
  • Exercise Tolerance / drug effects
  • Humans
  • Intermittent Claudication / drug therapy*
  • Intermittent Claudication / etiology
  • Intermittent Claudication / physiopathology
  • Peripheral Vascular Diseases / complications
  • Peripheral Vascular Diseases / drug therapy*
  • Peripheral Vascular Diseases / physiopathology
  • Quality of Life
  • Tetrazoles / adverse effects
  • Tetrazoles / pharmacokinetics
  • Tetrazoles / therapeutic use*
  • Treatment Outcome


  • Cardiovascular Agents
  • Tetrazoles
  • Cilostazol